metformin immediate-release + metformin delayed-release

**metformin immediate-release + metformin delayed-release** is a combination of two formulations of metformin: the immediate-release (EFB0026) and the delayed-release (EFB0027) forms. Metformin is an oral antihyperglycemic agent used primarily for the management of type 2 diabetes mellitus. Immediate-release metformin provides a rapid onset of action, while delayed-release is designed to minimize systemic bioavailability and target metformin activity in the distal intestine, potentially improving gastrointestinal tolerance and lowering the risk of some side effects. Both forms act by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity. The combination aims to optimize glycemic control by leveraging the benefits of both release profiles, while possibly minimizing systemic exposure to reduce side effects, especially in patients at risk for lactic acidosis. Developed for oral administration in the context of type 2 diabetes treatment, including in populations with renal impairment or gastrointestinal sensitivity to metformin[5][6][7].

Other names

EFB0026EFB-0026EFB 0026EFB0027EFB-0027EFB 0027